<DOC>
	<DOCNO>NCT00542919</DOCNO>
	<brief_summary>In study , patient get investigational drug . There comparator drug . This study evaluate three tumor type : T-cell lymphoma , Indolent B-cell lymphoma , Aggressive B-cell lymphoma . Each tumor type include several tumor subtypes : - T-cell lymphoma : Peripheral Cutaneous T-cell lymphoma ( PTCL , CTCL ) - Indolent B-cell lymphoma : Small lymphocytic lymphoma , follicular lymphoma ( Gr 1 2 ) marginal zone lymphoma - Aggressive B-cell lymphoma : Primary CNS lymphoma , follicular lymphoma ( Gr 3a 3b ) aggressive lymphoma prior clinical history indolent lymphoma .</brief_summary>
	<brief_title>A Study Patients With Non-Hodgkin 's Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Have measurable lesion Have recover prior chemotherapy Have estimate life expectancy least 12 week Hepatic : total bilirubin less equal 1.5 XULN ; ATL/AST le equal 2.0 x ULN ( less 5x liver metastasis present ) Renal : serum creatinine less equal 1.5XULN Adequate bone marrow reserve : platelet great equal 75 x 109 /L , absolute neutrophil count ( ANC ) great equal 1.0 x 09 /L Have second primary malignancy ( except adequately treat nonmelanomatous skin cancer , cancer consider cure surgical resection radiation ) . Antilymphoma therapy within past 3 week Unable swallow tablet Unable discontinue use carbamazepine , phenobarbital phenytoin least 14 day prior study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>